Other Clinical Trial - Endocrine Disrupting Chemicals & Hormones in ADHD

Status Enrolling by invitation

Clinical Trial Summary

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children and adolescents. Growth hormone and thyroid function are associated with both physical and neurocognitive development. Endocrine disrupting chemicals (EDCs) could disturb the normal function of endocrine systems, and further link to the pathophysiology of ADHD. In addition, whether methylphenidate for treating ADHD influences growth hormone and thyroid function of patients remains unclear.

Clinical Trial Description

Therefore, this study aims (1) to investigate the prospective role of EDCs, growth hormone and thyroid function in clinical manifestations of ADHD; and (2) to determine the influence of pharmacotherapy on growth hormone and thyroid function among patients with ADHD under a one-year methylphenidate treatment. Methods: In this two-year study, we will recruit 120 patients with ADHD (aged between 6 and 16) and 120 age- and gender-matched control subjects. Blood (10 ml) and urine (10 ml) will be obtained from each participant to analyze the levels of EDCs (Phthalates, Phenols and Parabens), growth hormone and thyroid function (TSH, T3, Free T4, T4, growth hormone, IGF-1and IGF-BP3). Behavior symptoms (ADHD-RS and SNAP-IV) and neuropsychological function (WISC, CPT and CATA) of each participant will be assessed. Patients with ADHD will receive treatment in a clinical practice and then will be followed up for 12 months. At the 12th month, the same procedures as those performed at the baseline will be replicated for patients with ADHD. This study will provide proof of the relationships of EDCs, endocrine systems and ADHD manifestations in clinical samples and further explain the biological pathogenesis of ADHD. In addition, this study will elucidate the influence of ADHD medications on growth hormone and thyroid function. Such information may become an important reference for future research and safety of pharmacotherapy for patients with ADHD. ;

Study Design

Related Conditions & MeSH terms

Attention Deficit Disorder with Hyperactivity
Attention Deficit Hyperactivity Disorder
Hyperkinesis

Clinical Trial Details

NCT number	NCT04970303
Study type	Observational
Source	Chang Gung Memorial Hospital
Contact
Status	Enrolling by invitation
Phase
Start date	July 12, 2019
Completion date	December 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06129396` - Effects of Aerobic Exercise Intervention in Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)	N/A
Completed	`NCT04779333` - Lifestyle Enhancement for ADHD Program 2	N/A
Recruiting	`NCT05935722` - Evaluation of a Home-based Parenting Support Program: Parenting Young Children	N/A
Completed	`NCT03148782` - Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase	N/A
Completed	`NCT04832737` - Strength-based Treatment Approach for Adults With ADHD	N/A
Recruiting	`NCT04631042` - Developing Brain, Impulsivity and Compulsivity
Recruiting	`NCT05048043` - Development of a Game-supported Intervention	N/A
Completed	`NCT03337646` - Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism	Phase 4
Not yet recruiting	`NCT06080373` - Formulation-based CBT for Adult Inmates With ADHD: A Randomized Controlled Trial	N/A
Not yet recruiting	`NCT06406309` - Settling Down for Sleep in ADHD: The Impact of Sensory and Arousal Systems on Sleep in ADHD	N/A
Completed	`NCT02477280` - Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance	Phase 4
Completed	`NCT02911194` - a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD)	N/A
Completed	`NCT02829970` - Helping College Students With ADHD Lead Healthier Lifestyles	N/A
Completed	`NCT02473185` - Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the QbTest	Phase 4
Completed	`NCT02390791` - New Technologies to Help Manage ADHD	N/A
Completed	`NCT02780102` - Cognitive-Motor Rehabilitation, Stimulant Drugs, and Active Control in the Treatment of ADHD	N/A
Completed	`NCT02555150` - A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD	Phase 3
Recruiting	`NCT04296604` - Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations	N/A
Recruiting	`NCT04175028` - Neuromodulation of Executive Function in the ADHD Brain	N/A
Completed	`NCT02580890` - Role of Transcranial Direct Current Stimulation (tDCS) in Patients With Attention Deficit Hyperactivity Disorder (ADHD)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Endocrine Disrupting Chemicals and Hormones in ADHD — ADHD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms